SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Status:
Suspended
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to
evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for
treating NAFLD in adolescents with obesity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute